D.A. Davidson & CO. trimmed its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 3.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 206,370 shares of the pharmacy operator’s stock after selling 8,257 shares during the period. D.A. Davidson & CO.’s holdings in CVS Health were worth $14,822,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sei Investments Co. boosted its holdings in CVS Health by 17.4% during the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after acquiring an additional 134,535 shares during the period. The Manufacturers Life Insurance Company increased its stake in CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after purchasing an additional 13,329 shares during the period. Treasurer of the State of North Carolina increased its stake in CVS Health by 1.3% in the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after purchasing an additional 7,588 shares during the period. HUB Investment Partners LLC lifted its position in shares of CVS Health by 25.0% during the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after purchasing an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of CVS Health by 8.0% during the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS is benefiting from a sector-wide lift after UnitedHealth delivered a large earnings beat and raised guidance, which helped improve sentiment across managed-care stocks including CVS. UNH Stock Flashes Buy Signal On Massive Earnings Beat
- Positive Sentiment: Truist reportedly reiterated a bullish stance with a new $118 price target, reinforcing the view that CVS still has room to run after recently hitting fresh highs. CVS Health Given New $118.00 Price Target at Truist Financial
- Positive Sentiment: CVS also continues to draw favorable analyst attention, with reports highlighting optimistic Wall Street recommendations and broader confidence in the stock’s fundamentals. Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
- Neutral Sentiment: Aetna’s provider survey showed improved payer trust and interest in digital tools, which is constructive for CVS Health’s Aetna segment but not likely a near-term stock mover. Aetna provider survey reveals increased payer trust and tangible benefits of digital tools to improve patient outcomes
- Negative Sentiment: Regulatory scrutiny remains a key overhang after reports that CVS Caremark reached a settlement with the FTC over rebate practices, pharmacy access, and transparency, which could pressure margins or invite more oversight. FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion
- Negative Sentiment: Some commentary also suggests CVS may be trading at a demanding valuation after its recent run, which could limit upside if earnings growth does not keep pace. The Real Price of Admission for CVS Health Stock
Insider Activity at CVS Health
CVS Health Stock Up 0.6%
NYSE:CVS opened at $106.51 on Friday. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $108.67. The company has a 50-day moving average of $98.64 and a 200 day moving average of $84.98. The firm has a market cap of $135.90 billion, a PE ratio of 46.92, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.
CVS Health (NYSE:CVS – Get Free Report) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period in the prior year, the business earned $2.25 EPS. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts anticipate that CVS Health Corporation will post 7.46 EPS for the current fiscal year.
CVS Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.
Analysts Set New Price Targets
A number of research analysts have recently commented on CVS shares. Sanford C. Bernstein upped their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. TD Cowen boosted their price objective on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Bank of America raised their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Robert W. Baird lifted their price target on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Twenty-one analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.38.
Read Our Latest Stock Analysis on CVS Health
CVS Health Company Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Further Reading
- Five stocks we like better than CVS Health
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
